Bill > HR890

This bill aims to prevent "double patenting" in pharmaceutical and biological product patents by introducing new provisions to limit patent term extensions. Specifically, the bill amends Title 35 of the United States Code to create a presumption that patent terms will be disclaimed for subsequent patents related to the same drug or biological product after the first patent expires, unless the patent holder can demonstrate by a preponderance of evidence that the patents cover patentably distinct inventions. The bill also requires the United States Patent and Trademark Office (USPTO) to conduct a comprehensive review of its patent examination procedures to improve practices for evaluating drug and biological product patents, with the goal of reducing improper patent term extensions. Within one year of enactment, the USPTO Director must submit a report to the House Judiciary Committee detailing the findings of this review and any recommended improvements to the patent examination process. The bill's name, the "Stopping Pharma's Ripoffs and Drug Savings For All Act", suggests its intent to limit pharmaceutical companies' ability to extend patent exclusivity and potentially lower drug costs.

Justice

https://www.congress.gov/bill/119th-congress/house-bill/890/all-info